Skip to main content
×
×
Home

Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial

  • Kirsten C. Morley (a1), Andrew Baillie (a2), Isabel Fraser (a1), Ainsley Furneaux-Bate (a1), Glenys Dore (a3), Michael Roberts (a4), Ahmed Abdalla (a5), Nghi Phung (a6) and Paul S. Haber (a7)...
Abstract
Background

There are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD).

Aims

To conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125).

Method

Patients (n = 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent.

Results

There was a significant effect of baclofen (composite groups) on time to lapse (χ2 = 6.44, P<0.05, Cohen's d = 0.56) and relapse (χ2 = 4.62, P<0.05, d = 0.52). A significant treatment effect of baclofen was observed for percentage days abstinent (placebo 43%, baclofen 30 mg 69%, baclofen 75 mg 65%; P<0.05). There was one serious adverse event (overdose) directly related to medication (75 mg).

Conclusions

Baclofen may be an effective treatment option for patients with ALD. However, given the profile of adverse events, the role for this medication might be best limited to specialist services.

Declaration of interest

None.

Copyright
Corresponding author
Correspondence: Kirsten C. Morley, Discipline of Addiction Medicine, Central Clinical School, Sydney Medical School, University of Sydney, 2006, New South Wales, Australia. Email: kirsten.morley@sydney.edu.au
References
Hide All
1World Health Organization. Global Information System on Alcohol and Health. WHO, 2015.
2Bosetti, C, Levi, F, Lucchini, F, Zatonski, WA, Negri, E, La, VC. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827–39.
3Tilg, H, Day, CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 2434.
4Addolorato, G, Mirijello, A, Leggio, L, Ferrulli, A, Landolfi, R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287–99.
5Colombo, G, Addolorato, G, Agabio, R, Carai, MA, Pibiri, F, Serra, S, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004; 6: 403–14.
6Maccioni, P, Colombo, G. Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. Alcohol 2009; 43: 555–8.
7Addolorato, G, Leggio, L, Ferrulli, A, Cardone, S, Vonghia, L, Mirijello, A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915–22.
8Chaignot, C, Weill, A, Ricordeau, P, Alla, F. Use in france of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI. Therapie 2015; 70: 443–53.
9Reynaud, M, Aubin, HJ, Trinquet, F, Zakine, B, Dano, C, Dematteis, M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol 2017; 52: 439–46.
10Ponizovsky, AM, Rosca, P, Aronovich, E, Weizman, A, Grinshpoon, A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abuse Treat 2015; 52: 2430.
11Addolorato, G, Caputo, F, Capristo, E, Domenicali, M, Bernardi, M, Janiri, L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol Alcohol 2002; 37: 504–8.
12Morley, KC, Baillie, A, Leung, S, Addolorato, G, Leggio, L, Haber, PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 2014; 49: 654–60.
13Beraha, EM, Salemink, E, Goudriaan, AE, Bakker, A, de Jong, D, Smits, N, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 2016; 26: 1950–9.
14Muller, CA, Geisel, O, Pelz, P, Higl, V, Kruger, J, Stickel, A, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1167–77.
15Morley, KC, Leung, S, Baillie, A, Haber, PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemp Clin Trials 2013; 36: 348–55.
16World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
17Sullivan, JT, Sykora, K, Schneiderman, J, Naranjo, CA, Sellers, EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353–7.
18Teesson, M, Sannibale, C, Reid, SC, Proudfoot, H, Gournay, K, Haber, P. Manual for Compliance Therapy in Alcohol Pharmacotherapy. NDARC Technical Report 157. NDARC, 2003.
19Sobell, LC, Maisto, SA, Sobell, MB, Cooper, A. Reliability of alcohol abusers’ self-reports of drinking behavior. Behav Res Ther 1979; 17: 157–60.
20Morley, KC, Teesson, M, Reid, SC, Sannibale, C, Thomson, C, Phung, N, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101: 1451–62.
21Morley, KC, Baillie, A, Leung, S, Sannibale, C, Teesson, M, Haber, PS. Is specialized integrated treatment for comorbid anxiety, depression and alcohol dependence better than treatment as usual in a public hospital setting? Alcohol Alcohol 2016; 51: 402–9.
22Child, CG, Turcotte, JG. Surgery and portal hypertension. In The Liver and Portal Hypertension (ed Child, CG): 5064. Saunders, 1964.
23Maddrey, WC, Boitnott, JK, Bedine, MS, Weber, FL, Mezey, E, White, RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75 (2): 193–9.
24Kamath, PS, Kim, WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45 (3): 797805.
25Skinner, HA, Allen, BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 1982; 91: 199209.
26Flannery, B, Volpicelli, J, Pettinati, H. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23: 1289–95.
27Lovibond, PF, Lovibond, SH. Manual for the Depression Anxiety Stress Scales. Psychology Foundation of Australia, 1995.
28Bastien, CH, Vallieres, A, Morin, CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297307.
29Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 2233.
30Schulz, KF, Altman, DG, Moher, D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Br Med J 2010; 340: c332.
31Hallgren, KA, Witkiewitz, K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin Exp Res 2013; 37: 2152–60.
32Gupta, M, Verma, P, Rastogi, R, Arora, S, Elwadhi, D. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. Am J Drug Alcohol Abuse 2017; 43: 324–31.
33Garbutt, JC, Kampov-Polevoy, AB, Gallop, R, Kalkajuhl, L, Flannery, BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2012; 34: 1849–57.
34Hauser, P, Fuller, B, Ho, SB, Thuras, P, Kern, S, Dieperink, E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction 2017; 112: 1173–83.
35Behar, KL, Rothman, DL, Petersen, KF, Hooten, M, Delaney, R, Petroff, OA, et al. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 1999; 156: 952–4.
36Leggio, L, Lee, MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med 2017; 130: 124–34.
37Owens, L, Thompson, A, Rose, A, Gilmore, I, Pirmohamed, M, Richardson, P. A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol 2017; 62: 11–5.
38Yamini, D, Lee, SH, Avanesyan, A, Walter, M, Runyon, B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol 2014; 49: 453–6.
39Chick, J, Nutt, DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol 2012; 26: 205–12.
40Farokhnia, M, Schwandt, ML, Lee, MR, Bollinger, JW, Farinelli, LA, Amodio, JP, et al. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry 2017; 7: e1108.
41Leggio, L, Zywiak, WH, McGeary, JE, Edwards, S, Fricchione, SR, Shoaff, JR, et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav 2013; 103: 784–91.
42Leung, NY, Whyte, IM, Isbister, GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas 2006; 18: 7782.
43Rolland, B, Labreuche, J, Duhamel, A, Deheul, S, Gautier, S, Auffret, M, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 2015; 25: 1631–6.
44Dore, GM, Lo, K, Juckes, L, Bezyan, S, Latt, N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol Alcohol 2011; 46: 714–20.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 114
Total number of PDF views: 251 *
Loading metrics...

Abstract views

Total abstract views: 1850 *
Loading metrics...

* Views captured on Cambridge Core between 2nd May 2018 - 21st August 2018. This data will be updated every 24 hours.

Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial

  • Kirsten C. Morley (a1), Andrew Baillie (a2), Isabel Fraser (a1), Ainsley Furneaux-Bate (a1), Glenys Dore (a3), Michael Roberts (a4), Ahmed Abdalla (a5), Nghi Phung (a6) and Paul S. Haber (a7)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *